Pyxis Oncology, Inc. (PYXS) intrinsic value & 10-year financials
Pyxis Oncology, Inc. (PYXS) has a Graham intrinsic value of $21.91 per share. At $1.68 on Oct 17, 2026, the stock trades 92% below that value. Over the last 7 fiscal years revenue shrank 14.2% a year to $13.9M, with an average return on invested capital of -5385.1%.
- Graham intrinsic value
- $21.91
- Share price (Oct 17, 2026)
- $1.68
- Price vs Graham value
- 92% below
- Market cap
- $104.4M
- Revenue (FY2025)
- $13.9M
- Revenue growth (7-yr CAGR)
- -14.2%
- ROIC (10-yr avg)
- -5385.1%
- Free cash flow (FY2025)
- -$63.5M
PYXS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $13.9M | -$79.6M | -$1.28 | -$63.5M | -609.2% | -96.5% |
| FY2024 | $16.1M | -$77.3M | -$1.32 | -$57.9M | -554.1% | -67.9% |
| FY2023 | — | -$73.8M | -$1.85 | -$77.4M | — | -108.0% |
| FY2022 | — | -$120.7M | -$3.65 | -$95.7M | — | -26707.3% |
| FY2021 | — | -$76.0M | -$2.24 | -$35.9M | — | — |
| FY2020 | — | -$12.8M | — | -$11.6M | — | 54.4% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Pyxis Oncology, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Pyxis Oncology, Inc. has historically struggled to out-earn its cost of capital, averaging just -97.0% ROIC.
Pyxis Oncology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Pyxis Oncology, Inc. is modeled at -14.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $21.91 per share.